Consequently, the co-targeting of HIF-1α and altered metabolic pathways in pancreatic cancer- and metastasis-initiating cells and their differentiated progenies represent potential therapeutic strategies to counteract rapid PDAC progression, metastatic spread at distant sites, treatment resistance and disease relapse of this very aggressive and lethal disease. The gene discussed is HIF1A; the disease is pancreatic neoplasm.